Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

New TYK2 Inhibitors for Psoriasis Achieve High Clearance Rates in Randomized Trials



(MedPage Today) — DENVER — Two drug candidates to expand oral therapy options for psoriasis had similar and consistent performances in separate phase III clinical trials reported here.
The allosteric TYK2 inhibitor zasocitinib achieved at…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments